Latest Articles

Publication Date
Molecular and Immune Microenvironmental Changes Across Endometrial Lesions: A Comprehensive Immunohistochemical and Clinical Analysis of Progression From Benignity to Carcinoma.

Adenomyosis and endometriosis are estrogen-driven disorders with a recognized potential for malignant transformation, particularly through atypical endometriosis. The molecular and immune mechanisms underlying this progression remain incompletely understood. However, clinical …

Published: Dec. 24, 2025, midnight
Effectiveness of an anti-inflammatory diet before in vitro fertilisation in women with endometriosis: protocol for a randomised controlled trial.

Endometriosis is a common, benign, chronic inflammatory disease with multiple consequences, from chronic pain to systemic comorbidities and poor quality of life. As it usually affects people of reproductive age, …

Published: Dec. 23, 2025, midnight
ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer - Nasdaq

ENHERTU Gets Tenth Breakthrough Therapy Designation, Launches Phase 3 Trial In Endometrial Cancer Nasdaq

Published: Dec. 22, 2025, 11:34 a.m.
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - The AI Journal

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer The AI Journal

Published: Dec. 22, 2025, 7:31 a.m.
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer - itemonline.com

DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer itemonline.com

Published: Dec. 22, 2025, 7:30 a.m.
Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer - OncLive

Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer OncLive

Published: Dec. 22, 2025, 5:26 a.m.
New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial - geneonline.com

New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial geneonline.com

Published: Dec. 21, 2025, 12:34 p.m.
Brian Slomovitz: New Study on PARP Therapy Advances in Endometrial Cancer - Oncodaily

Brian Slomovitz: New Study on PARP Therapy Advances in Endometrial Cancer Oncodaily

Published: Dec. 19, 2025, 7:56 p.m.
Endometriosis as an immune-mediated disease: pathogenetic mechanisms and therapeutic strategies.

Endometriosis, which affects approximately 10% of women of reproductive age, is a complex inflammatory disease with significant immune system disturbances caused by an inadequate immune response to retrograde menstruation and …

Published: Dec. 18, 2025, midnight
Immunotherapy in Endometrial Cancer: Mechanisms, Clinical Evidence, and Future Directions - Frontiers

Immunotherapy in Endometrial Cancer: Mechanisms, Clinical Evidence, and Future Directions Frontiers

Published: Dec. 17, 2025, 5:24 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!